Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
The recommendations from the American Diabetes Association and the European Association for the Study of Diabetes encourage use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke
A study conducted in Australia found that general practitioners with specialization in diabetes care and subspecialist-led clinics reduced HbA1c levels by similar amounts in patients with complex type 2 diabetes.
A recent scientific statement on diabetes and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes on outcomes in heart failure; reviews pharmacological therapy and lifestyle modification; highlights the value
The updates were based on findings from the industry-funded CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial.
Adults with type 1 and type 2 diabetes should aim to spend more than 70% of each day in the target range of 70 to 180 mg/dL (3.9 to 10.0 mmol/L), which corresponds to an HbA1c level of about 7%, the consensus report said.
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.